

## **Ixazomib Citrate Market**

Market Report | 2025-05-01 | 275 pages | Datastring Consulting

### **AVAILABLE LICENSES:**

- Multi User License \$1399.00

### **Report description:**

#### Description

The market, for Ixazomib citrate was estimated at \$431.1 million in 2024; and it is anticipated to increase to \$691.7 million by 2030 with projections indicating a growth to around \$1.0 billion by 2035. This expansion represents a compound annual growth rate (CAGR) of 8.2% over the forecast period.

#### Segmentation

To see report segmentation please view the table of contents, or ask us for samples.

### **Table of Contents:**

Chapter 1: Executive Summary - Major Markets & Their Performance - Statistical Snapshots

Chapter 2: Research Methodology

2.1: Axioms & Postulates

2.2: Market Introduction & Research Methodology - Estimation & Forecast Parameters / Major Databases & Sources

Chapter 3: Market Dynamics

3.1: Market Overview - Drivers / Restraints / Opportunities / M4 Factors

3.2: Market Trends

3.2.1: Introduction & Narratives

3.2.2: Market Trends - Impact Analysis (Short, Medium & Long Term Impacts)

3.3: Supply Chain Analysis

3.4: Porter's Five Forces - Suppliers & Buyers' Bargaining Power, Threat of Substitution & New Market Entrants, Competitive Rivalry

Chapter 4: Global Ixazomib Citrate Market Size, Opportunities & Strategic Insights, by Drug Formulation

4.1: Oral Administration

4.2: Injectable Form

Chapter 5: Global Ixazomib Citrate Market Size, Opportunities & Strategic Insights, by Patient Types

5.1: Relapsed/Refractory Patients

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 5.2: Newly Diagnosed Patients
- 5.3: Maintenance Therapy Patients
- Chapter 6: Global Ixazomib Citrate Market Size, Opportunities & Strategic Insights, by Therapeutic Application
  - 6.1: Multiple Myeloma
  - 6.2: Systemic Light-chain Amyloidosis
  - 6.3: Relapsed / Refractory MCL
- Chapter 7: Global Ixazomib Citrate Market Size, Opportunities & Strategic Insights, by Distribution Channel
  - 7.1: Hospital Pharmacies
  - 7.2: Specialty Clinics
  - 7.3: Retail Pharmacies
- Chapter 8: Ixazomib Citrate Market, by Region
  - 8.1: North America Ixazomib Citrate Market Size, Opportunities, Key Trends & Strategic Insights
    - 8.1.1: U.S.
    - 8.1.2: Canada
  - 8.2: Europe Ixazomib Citrate Market Size, Opportunities, Key Trends & Strategic Insights
    - 8.2.1: Germany
    - 8.2.2: France
    - 8.2.3: UK
    - 8.2.4: Italy
    - 8.2.5: The Netherlands
    - 8.2.6: Rest of EU
  - 8.3: Asia Pacific Ixazomib Citrate Market Size, Opportunities, Key Trends & Strategic Insights
    - 8.3.1: China
    - 8.3.2: Japan
    - 8.3.3: South Korea
    - 8.3.4: India
    - 8.3.5: Australia
    - 8.3.6: Thailand
    - 8.3.7: Rest of APAC
  - 8.4: Middle East & Africa Ixazomib Citrate Market Size, Opportunities, Key Trends & Strategic Insights
    - 8.4.1: Saudi Arabia
    - 8.4.2: United Arab Emirates
    - 8.4.3: South Africa
    - 8.4.4: Rest of MEA
  - 8.5: Latin America Ixazomib Citrate Market Size, Opportunities, Key Trends & Strategic Insights
    - 8.5.1: Brazil
    - 8.5.2: Mexico
    - 8.5.3: Rest of LA
  - 8.6: CIS Ixazomib Citrate Market Size, Opportunities, Key Trends & Strategic Insights
    - 8.6.1: Russia
    - 8.6.2: Rest of CIS
- Chapter 9: Competitive Landscape
  - 9.1: Competitive Dashboard & Market Share Analysis
  - 9.2: Company Profiles (Overview, Financials, Developments, SWOT)
    - 9.2.1: Takeda Pharmaceuticals
    - 9.2.2: Millenium Pharmaceuticals Inc
    - 9.2.3: Celgene Corporation

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

- 9.2.4: Bristol-Myers Squibb Company
- 9.2.5: Novartis AG
- 9.2.6: Johnson & Johnson
- 9.2.7: AstraZeneca
- 9.2.8: Pfizer Inc
- 9.2.9: Amgen Inc
- 9.2.10: Sanofi S.A.
- 9.2.11: Bayer AG
- 9.2.12: Eli Lilly and Company

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: [support@scotts-international.com](mailto:support@scotts-international.com)

[www.scotts-international.com](http://www.scotts-international.com)

## Ixazomib Citrate Market

Market Report | 2025-05-01 | 275 pages | Datastring Consulting

To place an Order with Scotts International:

- ☐ - Print this form
- ☐ - Complete the relevant blank fields and sign
- ☐ - Send as a scanned email to support@scotts-international.com

### ORDER FORM:

Select license	License	Price
	Multi User License	\$1399.00
		VAT
		Total

\*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

\*\* VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		
Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2025-06-08"/>
		Signature	<input type="text"/>

**Scotts International. EU Vat number: PL 6772247784**

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com